Literature DB >> 2317223

Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations.

D Degiannis1, J R Seibold, M Czarnecki, J Raskova, K Raska.   

Abstract

Plasma levels of soluble interleukin-2 receptors (sIL-2R) were measured by an enzyme-linked immunosorbent assay in 79 patients with systemic sclerosis (SSc). These levels were significantly elevated in SSc patients, compared with normal controls (mean +/- SEM 866.0 +/- 63.6 units/ml versus 293.0 +/- 20.5; P less than 0.001). Soluble IL-2R levels were highest in patients with generalized disease, were strongly associated with mortality (P less than 0.001) and inversely correlated with disease duration (P = 0.003), but were not related to sex, age, specific visceral involvement, serologic status, peripheral lymphocyte count, or therapy. Levels of sIL-2R in the supernatants of peripheral blood mononuclear cells were low in patients and controls, and showed comparable increases following phytohemagglutinin stimulation. Exposure of peripheral blood mononuclear cells to laminin did not induce sIL-2R release. Circulating IL-2 levels were comparably low in patients and controls. Our findings suggest the presence of lymphocyte activation in SSc, and further suggest that measurement of sIL-2R may prove to be a useful laboratory technique for assessing disease activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2317223     DOI: 10.1002/art.1780330310

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  28 in total

1.  Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation.

Authors:  G Valentini; A Baroni; K Esposito; C Naclerio; E Buommino; A Farzati; G Cuomo; B Farzati
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

2.  European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes.

Authors:  G Valentini; A Della Rossa; S Bombardieri; W Bencivelli; A J Silman; S D'Angelo; M M Cerinic; J F Belch; C M Black; P Bruhlmann; L Czirják; A De Luca; A A Drosos; C Ferri; A Gabrielli; R Giacomelli; G Hayem; M Inanc; N J McHugh; H Nielsen; M Rosada; R Scorza; J Stork; A Sysa; F H van den Hoogen; P J Vlachoyiannopoulos
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

3.  Interleukin-2 receptor gene polymorphism in Chinese patients with systemic lupus erythematosus.

Authors:  Chang-Hai Tsai; Chung-Ming Huang; Sui-Foon Lo; Lei Wan; Fuu-Jen Tsai
Journal:  Rheumatol Int       Date:  2006-02-25       Impact factor: 2.631

4.  Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis.

Authors:  H U Scherer; G-R Burmester; G Riemekasten
Journal:  Ann Rheum Dis       Date:  2006-09       Impact factor: 19.103

Review 5.  [Laboratory diagnostics for systemic sclerosis].

Authors:  R Mierau; A Roers; E Genth
Journal:  Z Rheumatol       Date:  2007-05       Impact factor: 1.372

6.  Relations between surface expression of the interleukin-2 receptor and release of the soluble form of the receptor in cultured mononuclear cells from patients with rheumatoid arthritis or systemic lupus erythematosus.

Authors:  M Itoh; Y Goto; Y Ohta; Y Goto; H Ohashi
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

7.  Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis.

Authors:  Xiang Guo; Brandon W Higgs; Anne C Bay-Jensen; Morten A Karsdal; Yihong Yao; Lorin K Roskos; Wendy I White
Journal:  J Invest Dermatol       Date:  2015-05-20       Impact factor: 8.551

Review 8.  Biomarkers in systemic sclerosis.

Authors:  Susan V Castro; Sergio A Jimenez
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

9.  Serum markers of T cell activation in relapses of Wegener's granulomatosis.

Authors:  C A Stegeman; J W Tervaert; M G Huitema; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

10.  Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.

Authors:  Katrin Schmidt; Lorena Martinez-Gamboa; Susan Meier; Christian Witt; Christian Meisel; Leif G Hanitsch; Mike O Becker; Doerte Huscher; Gerd R Burmester; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2009-07-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.